The Therapeutic Effect of Dysthyroid Optic Neuropathy
Thyroid Eye Disease
About this trial
This is an interventional other trial for Thyroid Eye Disease
Eligibility Criteria
Inclusion Criteria:
- Ability to perform visual fields and VEP examination Without any serious systemic diseases Without any surgery on eyes in six months
Exclusion Criteria:
- With any serious systemic diseases With any surgery on eyes in six months
Sites / Locations
- Zhongshan Opthalmic CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Orbital decompression combined MPT
Separate MPT
Orbital decompression was performed by the same doctor with rich clinical experience. MPT should be implemented in the patients with obvious thyroid disorder before orbital decompression surgery which should only be performed when thyroid function was stabilized. The surgery was performed under general anesthesia. An arcuate incision was made in the skin 2 mm below the lower eyelid margin, and the tissue under the incision were separated to the periorbita and orbital septum. Part of the medial orbital wall, inferior orbital wall and partial tissue of ethmoidal sinus were removed, and an appropriate amount of adipose tissue was excised. MPT was conducted after the surgery, at a dose of 1g methylprednisolone per day through intravenous injection for 3 consecutive days with a total amount of 3g methylprednisolone. After 3 days of intravenous injection of methylprednisolone, prednisone was orally taken by the patients at a dose of 30 mg/day which was gradually reduced.
MPT was conducted after the surgery, at a dose of 1g methylprednisolone per day through intravenous injection for 3 consecutive days with a total amount of 3g methylprednisolone. After 3 days of intravenous injection of methylprednisolone, prednisone was orally taken by the patients at a dose of 30 mg/day which was gradually reduced.